Keeping Track: Novartis' Ribociclib, Tesaro's Niraparib Submitted; Catalyst Clears Path For Firdapse Resubmission
Executive Summary
In retrospect, the European Society for Medical Oncology meeting was a showcase for pivotal trial data included in a burst of targeted therapy new drug applications, and more drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Keeping Track: US FDA Enters Year's Final Stretch With Tsunami Of Novel Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Spring Awakening: NDA Submissions To Watch For
If companies meet their publicly stated NDA filing targets, at least four breakthrough-designated therapies will arrive at US FDA in March.
Keeping Track: FDA Approves Novel HIV Treatment, New Dosing Regimen For Opdivo; Another Rare Pediatric Disease Designation For Prometic
The latest drug development news and highlights from our US FDA Performance Tracker.